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OBJECTIVE — The study aims to test whether biological interaction between hyperglycemia
and albuminuria can explain the inconsistent ﬁndings from epidemiological studies and clinical
trials about effects of hyperglycemia on stroke in type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Atotalof6,445HongKongChinesepatients
withtype2diabetesandfreeofstrokeatenrollmentwerefollowedupforamedianof5.37years.
Spline Cox proportional hazard regression was used to obtain hazard ratio curves, which were
used to identify cutoff points of A1C and spot urinary albumin–to–creatinine ratio for increased
ischemic stroke risk. The identiﬁed cutoff point of A1C was used to check biological interaction
between A1C and albuminuria (micro- and macroalbuminuria). The biological interaction was
estimated using relative excess risk due to interaction (RERI), attributable proportion due to
interaction (AP), and synergy index.
RESULTS — During the follow-up period, 4.45% (n  287) of patients developed ischemic
stroke. A1C was associated with increased hazard ratios of ischemic stroke in a near-linear
manner except for two points—6.2 and 8.0%—where the slope between these two points
accelerated. For A1C values 6.2%, the presence of micro/macroalbuminuria did not confer
additional risk, while signiﬁcant biological interaction between A1C and micro/
macroalbuminuriaforvalues6.2%wasobserved(RERI0.92,95%CI0.16–1.68,andAP0.40,
0.01–0.78).
CONCLUSIONS — A1C 6.2% and micro/macroalbuminuria interact to markedly in-
crease the ischemic stroke risk, which explains a large proportion of risk in patients with type 2
diabetes harboring both risk factors.
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S
everal large cohort studies have
demonstratedthathyperglycemiaor
type 2 diabetes is associated with an
elevated risk in stroke (1) and cardiovas-
cular death (2). The Diabetes Control and
Complications Trial (DCCT) veriﬁed that
glycemic control in type 1 diabetes re-
duced the incidence rate of cardiovascu-
lar disease, including stroke (3).
However, in type 2 diabetes, neither indi-
vidual randomized clinical trials nor
meta-analysis of published randomized
controlled trials could convincingly and
consistently demonstrate the beneﬁcial
effects of glucose lowering on reducing
stroke incidence (4). Somewhat paradox-
ically, the UK Prospective Diabetes Study
(UKPDS) even reported a nonsigniﬁcant
increase in stroke incidence in the inten-
sive treatment arm (5).
There are two possible reasons for
theseinconsistentﬁndings.Oneisthetar-
get of glycemia is not low enough to re-
duce stroke risk. In this regard, the recent
premature discontinuation of the inten-
sive treatment arm of the ACCORD (Ac-
tion to Control Cardiovascular Risk in
Diabetes) study, in which there is an ex-
cessive number of deaths, largely due to
sudden death, in the intensive treatment
arm with a target A1C level 6% further
complicatesthepicture(6).Thesecondis
whether hyperglycemia has biological in-
teractionwithotherimportantriskfactors
such as hypertension or albuminuria to
givesufﬁcient“causes”forstroke.Accord-
ing to the Rothman model, there should
be sufﬁcient “causes” and component
“causes” in disease development (7). In
this regard, biological interaction indi-
cates that two risk factors are involved in
the same sufﬁcient “cause” of disease, or
pathway toward disease (8,9).
Albuminuria was a strong predictor
of stroke (10), cardiovascular death (11),
and all-cause death (12). Previously, we
have developed a hazard ratio (HR) curve
method to examine full-range relation-
ships between risk factors and outcomes
(13,14). In this analysis, we hypothesize
that hyperglycemia interacts with albu-
minuria,bothbeingpotentriskfactors,to
increasestrokeriskintype2diabetes.We
tested this hypothesis by applying the HR
curve (13,14) and biological interaction
(8,9)toascertaintheoptimaltargetofgly-
cemia and its interaction with albumin-
uria on ischemic stroke risk.
RESEARCH DESIGN AND
METHODS— Detailed description of
the cohort has been published previously
(12). Brieﬂy, the Hong Kong Diabetes
Registry was established at the Prince of
Wales Hospital, which served a catch-
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1995. Patients came from general practi-
tioners, community clinics, and other
specialty clinics and also included pa-
tientsdischargedfromthePrinceofWales
Hospital or other hospitals. Enrolled pa-
tients with hospital admissions within
6–8 weeks before assessment accounted
for10%ofallreferrals.Thepatientsun-
derwent a 4-h comprehensive assess-
ment, which was modiﬁed from the
European DIABCARE protocol (15) as
part of a quality improvement program of
the Prince of Wales Hospital Diabetes
Centre. Once a diabetic subject was en-
rolled, he or she will be observed until
time of death. Hong Kong has a heavily
subsidized health care system. The Hos-
pital Authority is the governing body of
all 42 public hospitals, 45 specialist out-
patient clinics, and 74 general outpatient
clinics and provides over 95% of acute
and chronic care to the 6.8 million popu-
lation.Ethicsapprovalwasobtainedfrom
the Chinese University of Hong Kong
Clinical Research Ethics Committee.
Written informed consent was obtained
from all patients for data analysis and re-
search purpose upon enrollment.
From 1995 to 2005, 7,920 diabetic
patients were enrolled in this registry. Pa-
tients excluded from this analysis in-
cluded 332 patients with type 1 diabetes
(deﬁned as acute presentation with dia-
betic ketoacidosis, heavy ketonuria
[3], or continuous requirement of in-
sulin within 1 year of diagnosis), 5 with
uncertain type 1 diabetes status, 61 with
non-Chinese or unknown nationality,
and 329 with past history of stroke, in-
cluding cardioembolism, ischemic, and
hemorrhagic stroke. Another 765 pa-
tientswithmissingvaluesonthevariables
used in the analysis were excluded, and
eventually 6,445 patients with complete
data were used in the analysis.
Clinical measurements
Assessment methods, deﬁnitions, and
laboratory assays have been reported pre-
viously (6–8). Brieﬂy, clinical examina-
tion and laboratory investigations were
performed after at least 8 h of fasting. A
sterile, random spot urine sample was
used to measure albumin-to-creatinine
ratio (ACR). Microalbuminuria was de-
ﬁned as ACR 2.5 and 25 mg/mmol in
men and 3.5 and 25 mg/mmol in
women. Macroalbuminuria was deﬁned
as ACR 25 mg/mmol in both sexes. The
abbreviated Modiﬁcation of Diet in Renal
Disease (MDRD) formula recalibrated for
Chinese (16) was used to estimate glo-
merular ﬁltration rate (eGFR) expressed
in ml/min per 1.73 m
2:
eGFR  186  SCR  0.011
1.154
 age
0.203  0.742 if female
 1.233
where SCR is serum creatinine expressed
as mol/l (originally expressed as mg/l,
now converted to mol/l) and 1.233 is
the adjusting coefﬁcient for Chinese.
Outcome measures
Details of hospital admissions were re-
trieved from the Hong Kong Hospital Au-
thority Central Computer System, which
records admissions to all public hospitals
in Hong Kong. These databases were
matched by a unique identiﬁcation num-
ber, the Hong Kong Identity Card num-
ber, which is compulsory for all residents
in Hong Kong. Hospital discharge diag-
noses coded by the International Classiﬁ-
cation of Diseases, Ninth Revision (ICD-9),
were used to identify ischemic stroke de-
ﬁned as nonfatal ischemic stroke (ICD-9
code 432–434, 436) or deaths from isch-
emic stroke (ICD-9 code 432–438). Isch-
emic stroke events from enrollment up to
30 July 2005 were recorded or otherwise
censored on 30 July 2005. All diagnoses
of ischemic stroke were conﬁrmed by the
attending physician on discharge based
on clinical ﬁndings and ascertained by
computed tomography of brain in accor-
dancewiththeHospitalAuthorityclinical
guidelines. Transient ischemic attack and
asymptomatic stroke were not included
in both the deﬁnition of ischemic stroke
end point and stroke history at baseline.
Statistical analysis
The Statistical Analysis System (Release
9.10) was used to perform the statistical
analysis (SAS Institute, Cary, NC). Cox
proportional hazard regression was used
to obtain HRs of A1C and ACR for isch-
emic stroke while controlling for covari-
ates. Restricted cubic spline is piecewise
cubic polynomials that are connected
across different intervals of a continuous
variable (17). It can ﬁt sharply curving
shapes with the additional advantage that
only k-1 parameters must be estimated (k
is the number of knots, which are used to
divide the covariate into piecewise cubic
polynomials)(17).Wehavedevelopedan
HR curve method to examine full-range
associations between risk factors and all-
cause death (14) and interrelationships of
risk factors for the risk of coronary heart
disease (CHD) (13). In this analysis, we
used the same method to examine full-
rangeassociationbetweenA1C,ACR,and
ischemic stroke and to choose cutoff
points if indicated and their interrelation-
ship for ischemic stroke risk (13,14,17).
Use of the selected cutoff points, A1C
and ACR, was initially stratiﬁed into two
levels. Then, recoding was performed ac-
cording to the requirements for calcula-
tion of biological interaction (8,9). Three
measures to examine biological interac-
tion (or additive interaction) are 1) rela-
tive excess risk due to interaction (RERI),
2) attributable proportion due to interac-
tion (AP), and 3) synergy index (S). The
RERI is the excess risk due to interaction
relative to the risk without exposure. AP
refers to the attributable proportion of
disease that is due to interaction among
individuals with both exposures. S is the
excess risk from exposure (to both expo-
sures)whenthereisinteractionrelativeto
the risk from exposure (to both expo-
sures)withoutinteraction(18).RERI0,
AP 0, and S 1 indicate biological in-
teraction. However, the RERI is the best
choice of measures using a proportional
hazards model (19).
A structured adjustment scheme was
usedtocontrolforcovariates.Besidesage,
sex, smoking status, and hypertension
status, we also adjusted for BMI, LDL and
HDL cholesterol, duration of diabetes,
eGFR,andbaselinedrugusevariables,in-
cluding lipid-lowering drugs, oral antidi-
abetic drugs, and insulin. Further
adjustment using spline terms of contin-
uous variables was also performed. The
proportional hazards assumption was
checked.
RESULTS
Characteristics of study patients
At enrollment, the median age of the co-
hort was 57 years (interquartile range
46–67 years), with a median duration of
diabetes of 5 years (interquartile range
1–10 years). During a median follow-up
period of 5.37 years (interquartile range
2.89–7.75 years), 4.45% (n  287) of
ischemic stroke events were recorded,
giving an incidence rate of 8.36 (95% CI
7.40–9.33) per 1,000 person-years. Pa-
tientswhodevelopedischemicstrokehad
signiﬁcantly higher A1C and ACR than
patients who remained free of ischemic
strokeduringthefollow-upperiod(Table
1). Patients with ischemic stroke were
older, were more likely to be smokers,
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poorer metabolic proﬁle, and were more
likely to have complications and to use
antihypertensive drugs, insulin, aspirin,
and antiplatelet drugs (Table 1).
A1C and albuminuria as risk factors
of ischemic stroke
Both A1C and ACR were risk factors of
ischemic stroke. A1C was associated with
HR in a nearly linear manner. Neverthe-
less, two points where the slopes of the
curves sharply changed, 6.2 and 8.0%,
were identiﬁable. The two A1C curves
with and without adjustment for ACR
started to separate from 6.2% onward
with marked divergence from 8.0% (Fig.
1A).
ACR was associated with ischemic
stroke roughly in a linear manner from 0
to 100 mg/mmol and from 150 mg/mmol
upwards. The two ACR curves with and
without adjustment for A1C started to
separate at a very low level, roughly at the
level of microalbuminuria. The separa-
tion of the two curves widened progres-
sively with increasing ACR (Fig. 1B).
Using A1C and ACR as categorical vari-
ables, either A1C 6.2% or albuminuria
was signiﬁcantly, and by itself indepen-
dently, associated with increased risk of
ischemic stroke (Table 2).
In multivariable models, cancer his-
tory (P  0.3654) was not signiﬁcant as a
covariate for ischemic stroke. Use of ACE
inhibitors or angiotensin II receptor
blockers was also nonsigniﬁcant in a sep-
arate multivariable model (1.03, 95% CI
0.76–1.40, P  0.8548). Additionally,
aspirin (P  0.4716), antiplatelets (P 
0.3958), antiarrhythmic drugs (P 
0.7724), glucocorticoids (P  0.9625),
Table 1—Baseline clinical and biochemical characteristics of the study cohort of type 2 diabetic patients
Nonischemic stroke Ischemic stroke P
n 6,158 287 —
Age (years) 56 (46–67) 68 (60–73) 0.0001*
Male sex 45.3 48.4 0.3012‡
BMI (kg/m
2) 24.7 (22.4–27.3) 24.7 (22.4–26.9) 0.8339*
Smoking 0.0003‡
Former smokers 13.9 19.5
Current smokers 18.9 24.7
Duration of diabetes (years) 5 (1–10) 9 (3–15) 0.0001*
Systolic blood pressure (mmHg) 133 (120–147) 144 (130–160) 0.0001*
Diastolic blood pressure (mmHg) 76 (69–83) 77 (70–85) 0.0364*
Hypertension 57.6 78.4 0.0001‡
A1C (%) 7.3 (6.4–8.5) 7.9 (6.8–9.2) 0.0001*
A1C 6.2% 81.0 90.9 0.0001‡
LDL cholesterol (mmol/l) 3.10 (2.50–3.80) 3.30 (2.70–4.00) 0.0002*
HDL cholesterol (mmol/l) 1.26 (1.07–1.50) 1.21 (1.03–1.46) 0.0096*
Triglyceride (mmol/l) 1.33 (0.94–1.95) 1.40 (0.98–2.05) 0.1051*
Total cholesterol (mmol/l) 5.10 (4.5–5.83) 5.30 (4.70–5.09) 0.0044*
ACR (mg/mmol) 1.79 (0.73–9.27) 9.03 (1.83–62.49) 0.0001*
Microalbuminuria 25.1 31.7 0.0001‡
Macroalbuminuria 15.3 34.8
eGFR (ml/min per 1.73 m
2) 106.1 (85.6–127.7) 89.3 (67.1–109.1) 0.0001*
Retinopathy 25.3 42.5 0.0001‡
Sensory neuropathy 25.2 40.4 0.0001‡
Peripheral arterial disease 5.3 12.2 0.0001‡
History of CHD 5.4 12.9 0.0001‡
History of cancer 2.2 0.7 0.0773‡
Drug use at baseline
Lipid-lowering drugs 13.4 13.2 0.958‡
ACE inhibitors/angiotensin II receptor
blockers 20.6 23.7 0.2050‡
Other antihypertensive drugs 34.2 46.0 0.0001‡
Oral antidiabetic drugs 62.4 59.6 0.3317‡
Insulin 17.3 25.4 0.0004‡
Aspirin§ 8.3 12.3 0.0345*
Other aspirin-containing drugs§ 0.1 0.0 1.0†
Antiplatelet drugs§ 8.5 13.1 0.0166*
Anti-arrhythmic drugs§ 0.3 0.4 0.5448†
Glucocorticoid§ 1.6 0.0 0.051†
Non-steroidal anti-inﬂammatory drugs§ 2.4 1.3 0.2751*
Dataaremedians(25thto75th)or%,unlessotherwiseindicated.Hypertensionwasdeﬁnedassystolicbloodpressure140mmHgordiastolicbloodpressure90
mmHg or using ACE inhibitors, angiotensin II receptor blockers, or other antihypertensive drugs. Microalbuminuria was deﬁned as ACR 2.5 and 25 mg/mmol
in men and 3.5 and 25 mg/mmol in women; macroalbuminuria was deﬁned as ACR 25 mg/mmol in both sexes. *Derived from the 	
2 test. †Derived from
Fisher’s exact test. ‡Derived from the Wilcoxon two-sample test. §Only in 5,362 patients who were enrolled in the cohort after 1 December 1996.
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drugs (P  0.6473) were all nonsigniﬁ-
cant for ischemic stroke in 5,362 patients
whowereenrolledonorafter1December
1996 and whose additional drug use data
were available.
Interactive effects of hyperglycemia
and albuminuria
Separate models testing micro- and mac-
roalbuminuria showed that albuminuria
was a signiﬁcant risk factor for ischemic
strokeforallA1ClevelsexceptwhenA1C
was 6.2% (Table 2). A1C 6.2% and
albuminuria were signiﬁcantly and inde-
pendently associated with increased
strokeriskafteradjustingforothercovari-
ates. When A1C and albuminuria were
put together in an interaction model, the
risk association only persisted in coexist-
enceofA1C6.2%andalbuminuria(Ta-
ble 2), which greatly increased stroke
risk, even after adjustment for all covari-
ates or their spline terms (Table 2). Mea-
sure of biological interaction between
A1C 6.2% and albuminuria was tested
positive for RERI and AP but not signiﬁ-
cant for S (Table 3).
Associations between albuminuria
and traditional risk factors
Additional analysis using logistic proce-
dureshowsthatbaselinealbuminuriawas
associated with hypertension (odds ratio:
2.77[95%CI2.44–3.16]),A1C(1.17per
% [1.14–1.21]), LDL cholesterol (1.09
per mmol/l [1.03–1.16]), and BMI (1.04
per kg/m
2, 1.03–1.06) after adjusting for
age, duration of diabetes, baseline drug
use, and other covariates.
CONCLUSIONS — Based on rela-
tively novel analysis, we have answered
twoimportantquestions:1)A1Cneedsto
be lowered to 6.2% to reduce the inci-
dence rate of ischemic stroke substan-
tially and 2) there is biological interaction
between A1C 6.2% and albuminuria;
put in another way, these two risk factors
interact to substantially increase ischemic
stroke risk in type 2 diabetes, an effect
that is more than summation. Based on
these ﬁndings, we infer that stroke risk
can be substantially reduced by lowering
A1C to 6.2% or by substantially reduc-
ingalbuminuriaifA1Ccannotbereduced
effectively and safely to 6.2%.
A meta-analysis of cohort studies
showed that every 1% increase in A1C
was associated with a 1.17-fold risk of
stroke (1). We have reported a 1.49-fold
increased risk of ischemic stroke per 1%
increase in A1C in Chinese patients with
type2diabetes(20).Theseincreasedrisks
maybeattributabletothehighprevalence
of albuminuria in our population—
estimatedat50–60%—thathasalsobeen
reported in other Asian populations (21).
In the landmark DCCT involving 1,441
patients with type 1 diabetes followed up
for 17 years (3), microalbuminuria was
moreprevalent(13vs.7%,P0.01)and
A1C was higher (9.1 vs. 7.4%, P  0.01)
in the conventional treatment group than
the intensive insulin treatment group,
with the latter conferring 42% risk reduc-
tion in any cardiovascular events. In the
UKPDS, which consists of 3,867 newly
diagnosed type 2 diabetes patients fol-
lowed up for 10 years (22), a 0.9% differ-
ence in achieved A1C between the
intensive and conventional treatment
groups was associated with nonsigniﬁ-
cantly higher stroke risk (relative risk
1.11, P  0.52). Our ﬁndings may pro-
vide an explanation for these discrepant
ﬁndingsbetweentype1andtype2diabe-
tes. In the UKPDS, over a 10-year period,
A1C in the intensive treatment group was
signiﬁcantly lower than that in the con-
ventional treatment group (P  0.0001).
However, A1C level in the intensive
treatment remained high (median: 7%,
interquartile range: 6.2–8.2%). Given
the near-linear relationship between
A1C and stroke rate and that many type
2 diabetic patients may have coexisting
albuminuria, it is conceivable that the
Figure1—Hazardratioofhyperglycemiaandalbuminuriaforischemicstrokeintype2diabetes.
The multivariable models are adjusted for sex, smoking status (current and ex), hypertension
(deﬁned as systolic/diastolic blood pressure 140/90 mmHg, on ACE inhibitors/angiotensin II
receptor blockers, or on other antihypertensive drugs), use of drugs at baseline (lipid-lowering
drugs, oral antidiabetic drugs, and insulin), and spline functions of systolic blood pressure, BMI,
HDLcholesterol,estimatedglomerularﬁltrationrate,anddurationofdiabetes.A:Dotted[upper]
line represents the multivariable model, not adjusted for ACR. Starred [lower] line represents the
multivariate model, adjusted for ACR. B: Dotted [upper] line represents the multivariable model,
not adjusted for A1C. Starred [lower] line represents the multivariate model, adjusted for A1C.
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mic control and albuminuria may ex-
plain the failure to reduce the stroke
rate.
Given the powerful risk associations
between microalbuminuria and cardio-
vascular complications in type 2 diabetes
and the lack of effective therapy to reduce
hyperglycemia without causing hypogly-
cemia, our data strongly support the ag-
gressive reduction of albuminuria to
compensate for our inability to reduce
A1C to 6.2% safely. To this end, we
further conﬁrm that albuminuria is a
marker of multiple risk factors, especially
remediable risk factors, including hyper-
tension, hyperglycemia, high BMI, and
high LDL cholesterol. Our ﬁndings are
particularly intriguing, since in the AD-
VANCE (Preterax and Diamicron Modi-
ﬁed Release Controlled Evaluation)
study, the use of the ACE inhibitor perin-
dopril in the intensive treatment arm
based on gliclazide and other sulfonyl-
ureas, aiming at a target of 6.5%, may
have enhanced the vasculoprotective ef-
fect of glycemic control by reducing albu-
minuria (23). The Heart Outcomes
PreventionEvaluation(HOPE)study(24)
alsoreportedthatramipril,anACEinhib-
itor, helped lower the risk of stroke by
33%, cardiovascular death by 37%, and
total mortality by 24%, an effect beyond
that due to a decrease in blood pressure.
Of note, in the HOPE study, ramipril
treatmentledtoalowerACRat1yearand
4 years of study.
Our study has several limitations.
First, the cutoff points of A1C, 6.2 and
8.0%, were chosen based on visual obser-
vation of characteristics of the hazard ra-
tio curve of A1C for ischemic stroke.
Second, only one measurement of ACR
and A1C was available for this analysis.
Third, this cohort was a clinic-based
rather than population-based cohort.
However, Hong Kong does not have a
comprehensive health insurance policy
and integrated primary health care sys-
tem. Thus, the majority of patients with
chronic illnesses are managed in public
hospitals more for ﬁnancial reasons than
disease severity. In Hong Kong, 90% of
patients diagnosed with diabetes were
treated in the public health sector (12).
An annualized rate of 16.43 per 1,000
person-years for mortality and 14.08 per
1,000 person-years for incident CHD in
the cohort were similar to those reported
in other community-based databases
Table 2—Hazard ratios for the risk of ischemic stroke in relation to A1C and albuminuria
Exposure
Number at
risk
Hazard
ratio 95% CI P
Basic models
Basic model 1*
A1C (per %) 6,445 1.10 1.03–1.17 0.0039
Albuminuria
Microalbuminuria vs. normoalbuminuria 1,635 1.43 1.06–1.94 0.0182
Macroalbuminuria vs. normoalbuminuria 1,042 2.13 1.54–2.95 0.0001
Hypertension: yes vs. no 3,776 1.50 1.10–2.06 0.0113
Glomerular ﬁltration rate (per 10 ml/min per 1.73 m
2) 6,445 0.97 0.93–1.02 0.2341
Basic model 2*
A1C 6.2 vs. 6.2% 5,555 1.73 1.15–2.60 0.0084
Micro/macroalbuminuria vs. normoalbuminuria 2,677 1.74 1.33–2.27 0.0001
Hypertension: yes vs. no 3,776 1.53 1.12–2.08 0.0075
Glomerular ﬁltration rate, per 10 ml/min per 1.73 m
2 6,445 0.96 0.92–1.00 0.0627
Basic model 3 (four individual models)‡
Micro/macroalbuminuria vs. normoalbuminuria in A1C 6.2% 1,194 1.25 0.56–2.76 0.5846
Micro/macroalbuminuria vs. normoalbuminuria in A1C 6.2–6.9% 1,422 2.16 1.23–3.80 0.0078
Micro/macroalbuminuria vs. normoalbuminuria in A1C 7.0–10.0% 3,129 1.81 1.28–2.56 0.0009
Micro/macroalbuminuria vs. normoalbuminuria in A1C 10.0% 700 2.22 1.05–4.70 0.0376
Interaction models
Interaction model 1†
A1C 6.2% and normoalbuminuria vs. others 2,974 1.66 0.93–2.98 0.0889
A1C 6.2% and micro/macroalbuminuria vs. others 400 2.18 1.01–4.70 0.0474
A1C 6.2% and micro/macroalbuminuria vs. others 2,277 5.11 2.91–8.70 0.0001
Interaction model 2*
A1C 6.2% and normoalbuminuria vs. others 2,974 1.35 0.75–2.44 0.3130
A1C 6.2% and micro/macroalbuminuria vs. others 400 1.17 0.54–2.56 0.6888
A1C 6.2% and micro/macroalbuminuria vs. others 2,277 2.46 1.38–4.39 0.0024
Interaction model 3§
A1C 6.2% and normoalbuminuria vs. others 2,974 1.30 0.72–2.35 0.3807
A1C 6.2% and micro/macroalbuminuria vs. others 400 1.10 0.50–2.40 0.8090
A1C 6.2% and micro/macroalbuminuria vs. others 2,277 2.32 1.30–4.16 0.0046
Microalbuminuria was deﬁned as ACR 2.5 and 25 mg/mmol in men and 3.5 and 25 mg/mmol in women; macroalbuminuria was deﬁned as ACR 25
mg/mmol in both sexes. *Adjusted for traditional risk factors including age, sex, smoking status (current and former), hypertension (deﬁned as systolic/diastolic
bloodpressure140/90mmHgoronACEinhibitors/angiotensinIIreceptorblockersorotherantihypertensivedrugs),BMI,HDLcholesterol,durationofdiabetes,
estimated glomerular ﬁltration rate, and use of drugs at baseline (lipid-lowering drugs, oral anti-diabetic drugs, and insulin). †Not adjusted for other covariates.
‡Adjusted for age, sex, current smoking status, and hypertension. §Adjusted for covariates listed in *, but spline was used for all the continuous covariates.
Hyperglycemia, albuminuria, and ischemic stroke
2298 DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008(12). Fourth, a small number of ischemic
eventsmightnothavebeenidentiﬁed,no-
tably due to emigration to other coun-
tries. However, this number is likely to be
few, since lack of insurance coverage is
likely to reduce the likelihood of emigra-
tion or acceptance of these high-risk pa-
tients by other countries as permanent
residents. Fifth, only baseline measure-
ments of risk factors such as A1C, ACR,
lipids, and drug use were available for the
present analysis. Metabolic proﬁle may
deteriorateovertimeand,asaresult,drug
use may increase substantially during the
long follow-up period. Sixth, we did not
have information on atrial ﬁbrillation or
inﬂammatory or immunological disorder
conditions. However, use of antiarrhyth-
mic drugs, glucocorticoids, and nonste-
roidal anti-inﬂammatory drugs in the
cohort was very low and not signiﬁcant
for ischemic stroke. Thus, these medical
conditions may not have major impacts
on the ﬁndings of the study.
In conclusion, based on a large pro-
spective cohort of patients with type 2 di-
abetes,weconﬁrmedthemarkedincrease
in the risk of ischemic stroke when A1C
6.2% and albuminuria coexist. These
ﬁndings have important therapeutic im-
plications given our current armamentar-
ium in lowering blood glucose. Until safe
and effective agents become available to
lower A1C to 6.2%, reducing albumin-
uria by aggressive control of multiple risk
factors, notably blood pressure and inhi-
bition of the renin-angiotensin system, is
ofcriticalimportancetoreducetheriskof
stroke in type 2 diabetes.
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